KRAS and non-small cell lung carcinoma: EMT phenotype is also thought to be associated with resistance to targeted therapy in EGFR-driven NSCLC [24, 25] and in ALK-rearranged NSCLC treated with ALK TKIs [26] as well as in K-Ras mutated cancers [27].